Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Objective: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer. Methods: Patients with HER2-negative breast cancer, who were pre-treated with anthracycline or taxanes i...

Full description

Bibliographic Details
Main Authors: Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan
Format: Article
Language:English
Published: China Anti-Cancer Association 2021-08-01
Series:Cancer Biology & Medicine
Subjects:
anlotinib
angiogenesis
her2-negative
breast cancer
ctdna
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1807

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1807

Similar Items